Outcome of Board Meeting

Nectar Lifesciences Ltd. Ref. No.: NLL/CS/2026- 703 August 14, 2026 1. National Stock Exchange of India Limited 2. BSE Limited Listing Department, Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, P J Towers, Dalal Street, Bandra (E), Mumbai 400 051 Mumbai 400 001 Symbol: NECLIFE Scrip Code: 532649 Sub: Outcome of Board Meeting Ref.: Regulation 30 and 33 of Securities and Exchange Board of India (“SEBI”) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulation”). Dear Sir/ Madam, We wish to inform you that the board of directors of Nectar Lifesciences Limited (“Company”) in their meeting held on August 14, 2026, have, inter-alia, noted, decided and approved the following matters: 1. The unaudited standalone and consolidated financial results for the quarter ended on June 30, 2026, which are enclosed herewith along with the limited review reports of the auditors thereon as Annexure- A; 2. Appointed Dr. Gunmala Suri (DIN: 11879344) as an Additional Director from August 15, 2026, till forthcoming Annual General meeting (“AGM”) as well as Non-Executive Non- Independent Director subject to approval of members at the forthcoming AGM of the Company with effect from August 15, 2026; The requisite details regarding appointment of Director required under the LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and as amended upto date, are provided in Annexure- B. 3. To convene the 31st AGM of the members of the Company on Friday, September 18, 2026; 4. To close the register of members and share transfer books from September 12, 2026, to September 18, 2026 (both days inclusive) for the purpose of AGM. Accordingly, the cut-off date, to ascertain the eligibility of members for remote e-voting and polling/ e- voting at AGM, is September 11, 2026, i.e., the date prior to the commencement of book closure; 5. The re-appointment of Mr. Sanjiv Goyal (DIN: 00002841), director, who retire by rotation, in the forthcoming AGM; 6. The proposal for appointment of Dr. Gunmala Suri (DIN: 11879344) as a regular director as well as Non-Executive Non-Independent Director with effect from August 15, 2026, Corporate Office: Plot No. 110, Industrial Area, Phase 1, Chandigarh 160 002, INDIA Registered Office: Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab- 140 507, INDIA Website: www.neclife.com, E-mail: nectar.info@neclife.com CIN: L21000PB1995PLC016664 Nectar Lifesciences Ltd. subject to approval of the members at the forthcoming AGM; 7. Reconstitution of the Audit Committee, Stakeholders Relationship Committee (“SRC”) and Corporate Social Responsibility Committee (“CSR”) w.e.f. August 14, 2026. Post reconstitution, the composition of the committees are as under: 1. Audit Committee S. Name of Committee Position in Nature of Directorship No. members Committee 1. Dr. Rupinder Tewari Chairperson Non-Executive Independent Director 2. Dr. Indu Pal Kaur Member Non-Executive Independent Director 3. Dr. Kuldip Kumar Member Non-Executive Independent Bhasin Director 4. Mr. Sushil Kapoor Member Whole-time Director & Chief Financial Officer (“CFO”) 2. SRC S. Name of Committee Position in Nature of Directorship No. members Committee 1. Dr. Kuldip Kumar Chairperson Non-Executive Independent Bhasin Director 2. Mr. Sanjiv Goyal Member Chairman & Managing Director 3. Mr. Sushil Kapoor Member Whole-time Director & CFO 3. CSR S. Name of Committee Position in Nature of Directorship No. members Committee 1. Dr. Kuldip Kumar Chairperson Non-Executive Independent Bhasin Director 2. Mr. Sanjiv Goyal Member Chairman & Managing Director 3. Mr. Sushil Kapoor Member Whole-time Director & CFO The Board Meeting commenced at 07:30 P.M. IST and concluded at 08:35 P.M. IST. Kindly take the same on record. Thanking you, Yours faithfully, For Nectar Lifesciences Limited (Sanjaymohan Singh Rawat) Company Secretary & Compliance Officer Corporate Office: Plot No. 110, Industrial Area, Phase 1, Chandigarh 160 002, INDIA Registered Office: Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab- 140 507, INDIA Website: www.neclife.com, E-mail: nectar.info@neclife.com CIN: L21000PB1995PLC016664 Annexure- A NECTAR LIFESCIENCES LIMITED Regd.Office: Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab- 140 507, INDIA, Email : cs@neclife.com, Website : www.neclife.com, [CIN: L21000PB1995PLC016664] Statement of Financial Results for the Quarter ended 30.06.2026 (Rs in Lacs) S. No. Particulars Standalone Consolidated Quarter Ended Year Ended Quarter Ended Year Ended 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 Unaudited Audited Unaudited Audited Unaudited Audited Unaudited Audited Continuing Operations I Income from Operations Sales 1.45 - - - 1.45 - - - Other operating Income 42.76 128.97 0.63 2 01.05 42.76 128.97 0.63 201.05 II Other Income 585.26 629.03 30.31 7 28.04 291.99 629.03 30.31 728.04 III Total Income (I + II) 6 29.47 7 58.00 30.94 929.09 336.20 7 58.00 30.94 929.09 IV Expenses (a) Cost of Materials consumed - - - - - - - - (b) Purchase of Stock in Trade 2.75 - - - 2.75 - - - (c) Changes in inventories of finished goods, work-in-progress and (1.38) - - - (1.38) - - - stock-in-trade (d) Employee benefits expense 103.28 125.36 2.02 1 90.36 106.37 126.22 2.04 191.22 (e) Finance costs 15.69 590.05 - 3,612.52 15.69 590.05 0.01 3,612.52 (f) Depreciation and amortisation expense 11.06 8.28 8.71 3 4.26 11.06 8.28 8.66 34.26 (g) Other expenses 2 ,663.56 5 ,726.27 6.68 5,878.94 2 ,663.66 5 ,726.31 6.69 5,878.98 Total Expenses (IV) 2 ,794.96 6 ,449.96 17.41 9,716.08 2 ,798.15 6 ,450.86 17.40 9,716.98 V Profit/(Loss) before exceptional items and tax from continuing (2,165.49) (5,691.96) 13.53 ( 8,786.99) (2,461.95) (5,692.86) 13.54 ( 8,787.89) operations (III- IV) VI Exceptional item - - - - - - - - VII Profit/(Loss) before from continuing operations (V- VI) (2,165.49) (5,691.96) 13.53 ( 8,786.99) (2,461.95) (5,692.86) 13.54 ( 8,787.89) VIII Tax Expense of continuing operations Current Tax - - - - - - - - Deferred Tax (819.87) (1,971.36) 4.73 (3,052.88) (890.08) (1,971.64) 4.73 (3,053.16) IX Profit for the period from continuing operations (VII-VIII) (1,345.62) (3,720.60) 8.80 ( 5,734.11) (1,571.87) (3,721.22) 8.81 ( 5,734.73) Discontinued Operations Profit before tax from discontinued operations 49.35 (7,320.58) (9,688.97) ( 53,765.51) 49.35 (7,320.58) (9,688.97) ( 53,765.51) Exceptional item (Gain on slump sale) - - - 1 6,337.32 - - - 16,337.32 Tax expenses of discontinued operations 17.25 (4,249.38) (3,357.08) ( 13,873.82) 17.25 (4,249.38) (3,357.08) ( 13,873.82) Profit for the period from discontinued operations 32.10 (3,071.20) (6,331.89) ( 23,554.37) 32.10 (3,071.20) (6,331.89) ( 23,554.37) Total Profit for the period (1,313.52) (6,791.80) (6,323.09) ( 29,288.48) (1,539.77) (6,792.42) (6,323.08) ( 29,289.10) Other Comprehensive Income Items that will not be reclassified subsequently to profit or loss Remeasurement of the net defined benefit liability/asset - 12.18 - 1 2.18 - 12.18 - 12.18 Income Tax relating to items that will not be reclassified to profit or - (4.26) - (4.26) - (4.26) - ( 4.26) loss Items that will be reclassified subsequently to profit or loss Foreign Exchange Translation Reserve (Net of Tax) - - - - - 0.02 0.01 0.03 Income Tax relating to items that will be reclassified to profit or loss - - - - - (0.01) - ( 0.01) Total Other Comprehensive Income, (Net of Tax) - 7.92 - 7.92 - 7.93 0.01 7 .94 Total Comprehensive Income for the period (1,313.52) (6,783.88) (6,323.09) ( 29,280.56) (1,539.77) (6,784.49) (6,323.07) ( 29,281.16) X Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up) (before and after exceptional item) a) Basic continuing operations (In Rs.) (0.69) (1.85) - (2.62) (0.81) (1.85) - ( 2. [Showing first 8,000 characters — download PDF for full document]